Physician profile
Faridoon Khan
NPI 1760446082
$2,504.36
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $218 · 2021: $1,030 · 2022: $80.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $409.72 | 2019 | |
| Eisai INC. | $342.84 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $310.35 | 2021 | |
| Glaxosmithkline, LLC. | $249.80 | 2021 | |
| Amgen INC. | $184.64 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $125.00 | 2020 | |
| Mallinckrodt Enterprises LLC | $122.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.25 | 2021 | |
| Epizyme, INC. | $109.85 | 2021 | |
| Sunovion Pharmaceuticals INC. | $108.80 | 2019 | |
| Lilly USA, LLC | $95.16 | 2019 | |
| Merck Sharp & Dohme LLC | $91.82 | 2019 | |
| Puma Biotechnology, INC. | $91.67 | 2021 | |
| G1 Therapeutics, INC. | $80.28 | 2022 | |
| Janssen Biotech, INC. | $60.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faridoon Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.